Files and links (1)
Open Access CC BY V4.0
Journal article
Real-World Effectiveness of Ocrelizumab in Relapsing Multiple Sclerosis: an MSBase Registry Sub-Study
Multiple sclerosis and related disorders, Vol.106, 106885
2025
Abstract
Introduction
The MSOCR-R study evaluates the long-term effectiveness of ocrelizumab (OCR) in patients with relapsing multiple sclerosis (RMS) in real-world clinical settings.
Methods
MSOCR-R is an ongoing, prospective, longitudinal, observational cohort study of people with RMS newly treated with OCR, using data from the international MSBase registry. The study started in July 2018, and data collected up to October 2023 were analyzed. Outcomes were confirmed disability worsening (CDW), progression independent of relapses (PIRA), and no evidence of disease activity (NEDA-3: absence of relapse, 24-week CDW, or imaging activity).
Results
Overall, 1011 patients were enrolled (18.1% initiated OCR first-line therapy; 81.9% switched from previous treatment), with a median time of 3.4 years on OCR treatment. About 67% of patients were females. At OCR initiation, mean age was 41.9 years, median disease duration was 10.4 years, and median Expanded Disability Status Scale score was 3.0. The 4-year Kaplan–Meier probabilities of 24-week CDW or PIRA were 25.2% (95% CI 21.6–29.1) and 21.9% (95% CI 18.3–25.2), respectively. Annualized relapse rate substantially decreased from 0.58 (95% CI 0.53–0.63) before OCR to 0.05 (95% CI 0.04–0.06) after treatment initiation. NEDA-3 was assessed in 366 patients and the probability of achieving NEDA-3 was 39.7% (95% CI 36.0–43.5) at 4 years. Persistence on OCR was 88.0% (95% CI, 85.2–90.3) at 4 years. Better clinical outcomes were consistently observed among the first-line treatment cohort.
Conclusion
The MSOCR-R study provides strong real-world evidence of OCR effectiveness in people with RMS.
Details
- Title
- Real-World Effectiveness of Ocrelizumab in Relapsing Multiple Sclerosis: an MSBase Registry Sub-Study
- Authors/Creators
- Helmut Butzkueven - Monash UniversityPamela Farr - The Alfred HospitalSerkan Ozakbas - İzmir University of EconomicsCavit Boz - Karadeniz Technical UniversityTomas Kalincik - The University of MelbourneLisa Taylor - CORe, Department of Medicine, University of Melbourne, Melbourne, AustraliaAnneke Van Der Walt - Monash UniversityRaed Alroughani - Amiri HospitalKatherine Buzzard - Monash UniversityOlga Skibina - Monash UniversityJeannette Lechner-Scott - University Newcastle, Newcastle, AustraliaGuy Laureys - Ghent University HospitalMurat Terzi - Faculty (United Kingdom)Vincent Van Pesch - Cliniques Universitaires Saint-LucFrancois Grand-Maison - Montreal Neurological Institute and HospitalMichael Barnett - The University of SydneyAllan Kermode - University of Western Australia, Nedlands, AustraliaJose Luis Sanchez Menoyo - Hospital de GaldakaoJuan Rojas - Hospital Universitario de CEMIC, Buenos Aires, ArgentinaBarbara Willekens - Antwerp University HospitalMatteo Foschi - Ospedale "Santa Maria delle Croci" di RavennaCristina Ramo-Tello - Trias (Greece)Eli Skromne - Hospital Angeles de las Lomas, Instituto Mexicano de Neurociencias, Valle de las Palmas, MexicoPetra Dirks - F. Hoffmann-La Roche Ltd, Basel, SwitzerlandErwan Muros-Le Rouzic - F. Hoffmann-La Roche Ltd, Basel, SwitzerlandTim Spelman - Karolinska InstitutetMSBase investigators
- Publication Details
- Multiple sclerosis and related disorders, Vol.106, 106885
- Publisher
- Elsevier B.V.
- Identifiers
- 991005831734207891
- Copyright
- © 2025 The Authors.
- Murdoch Affiliation
- Institute for Immunology and Infectious Diseases
- Language
- English
- Resource Type
- Journal article
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: SDGs in the Output
Metrics
15 Record Views